바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.75 No.6
Citation Share

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.75 no.6, pp.256-259











& (2013). Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis. Tuberculosis & Respiratory Diseases, 75(6), 256-259.
  • Downloaded
  • Viewed
PDF Download

Abstract

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.

keywords
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib, Lung Diseases, Interstitial

Reference

1.

Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.

2.

Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4.

3.

Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, et al. Imatinib- mesylate induced interstitial pneumonitis in two CML patients. Tuberc Respir Dis 2011;71:210-5.

4.

Lee JW, Kim HJ, Kim KJ, Shin KC, Hong YH, Chung JH, et al. A case of imatinib-mesylate associated hypersensitivity pneumonitis. Tuberc Respir Dis 2005;59:423-6.

5.

Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-43.

6.

Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004;18:645-6.

7.

Snyder LS, Hertz MI, Peterson MS, Harmon KR, Marinelli WA, Henke CA, et al. Acute lung injury: pathogenesis of intraalveolar fibrosis. J Clin Invest 1991;88:663-73.

8.

Walsh J, Absher M, Kelley J. Variable expression of plateletderived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 1993;9:637-44.

9.

Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59.

10.

Seki N, Ito A, Watanabe K, Shibakuki R, Seto T, Uematsu K, et al. Irreversible imatinib-induced pneumonitis following longterm imatinib administration. Intern Med 2007;46:1941-2.

11.

Delomas T, Darne C, Besson C. Lack of recurrence of imatinib- induced interstitial lung disease with nilotinib. Leuk Lymphoma 2012;53:332-3.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy